Latest News in the pharma Industry

Research & Development

BMS receives FDA approval for Opdivo, the only treatment to deliver significant overall survival in advanced renal cell carcinoma

BMS receives FDA approval for Opdivo, the only treatment to deliver significant overall survival in advanced renal cell carcinoma

24 Nov 2015

Fifth approval for Opdivo in 12 months.

Read more 
Biogen announces Benepali (etanercept) is the first biosimilar of Enbrel to receive a positive opinion from CHMP

Biogen announces Benepali (etanercept) is the first biosimilar of Enbrel to receive a positive opinion from CHMP

20 Nov 2015

Pending EC approval, Biogen would commercialize Benepali in the EU.

Read more 
New long-term data on Opdivo and the Opdivo + Yervoy regimen shows survival benefit across lines of therapy in advanced melanoma

New long-term data on Opdivo and the Opdivo + Yervoy regimen shows survival benefit across lines of therapy in advanced melanoma

19 Nov 2015

Longest follow-up for the Opdivo + Yervoy regimen from study 004 shows 3-year overall survival rate of 68% across Phase I dosing cohorts.

Read more 
BMS to sell its HIV R&D portfolio to ViiV Healthcare

BMS to sell its HIV R&D portfolio to ViiV Healthcare

18 Dec 2015

Transactions are consistent with the evolution of BMS’s strategic focus, including the decision to discontinue its discovery efforts in virology announced in June.

Read more 
Merck and Pfizer receive FDA Breakthrough Therapy Designation for avelumab in metastatic Merkel cell carcinoma

Merck and Pfizer receive FDA Breakthrough Therapy Designation for avelumab in metastatic Merkel cell carcinoma

18 Nov 2015

If approved, avelumab could potentially become the first immunotherapy to treat metastatic MCC.

Read more 
Lucentis effective for proliferative diabetic retinopathy

Lucentis effective for proliferative diabetic retinopathy

18 Nov 2015

NIH-funded clinical trial marks first major advance in therapy in 40 years.

Read more 
FLAME study shows superiority of Novartis' Ultibro Breezhaler over Seretide in reducing COPD exacerbations

FLAME study shows superiority of Novartis' Ultibro Breezhaler over Seretide in reducing COPD exacerbations

17 Nov 2015

First large-scale study to confirm Ultibro Breezhaler is an effective steroid-free option that both reduces exacerbations and improves lung function in COPD patients with one or more exacerbations in the past year, compared to Seretide.

Read more 
Concert Pharmaceuticals achieves $2 million milestone from Avanir Pharmaceuticals for Phase III Initiation of AVP-786 for agitation in patients with Alzheimer’s disease

Concert Pharmaceuticals achieves $2 million milestone from Avanir Pharmaceuticals for Phase III Initiation of AVP-786 for agitation in patients with Alzheimer’s disease

16 Nov 2015

The collaboration agreement between Concert and Avanir provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan (d-DM) compounds.

Read more 
Positive Phase I/II interim data of Bimatoprost sustained-release implant for IOP therapy in glaucoma

Positive Phase I/II interim data of Bimatoprost sustained-release implant for IOP therapy in glaucoma

16 Nov 2015

Bimatoprost SR is a biodegradable, intracameral implant providing slow release of bimatoprost and is a differentiated approach to treat glaucoma beyond conventional daily eye drop treatments because it is a non-daily treatment administered by a physici...

Read more 
Allergan presents data at the 2015 American Academy of Ophthalmology Annual Meeting in Las Vegas

Allergan presents data at the 2015 American Academy of Ophthalmology Annual Meeting in Las Vegas

13 Nov 2015

Five oral presentations include “Long-Term Response to Anti-VEGF Therapy for DME Can be Predicted After 3 Injections — An Analysis of Protocol I Data”.

Read more 
FDA approves Roche’s Cotellic in combination with Zelboraf in advanced melanoma

FDA approves Roche’s Cotellic in combination with Zelboraf in advanced melanoma

12 Nov 2015

FDA approval underscores the important role of targeted medicines to help people with BRAF V600 mutation-positive advanced melanoma.

Read more 
Concert Pharmaceuticals initiates Phase I multiple ascending dose trial with CTP-656 for cystic fibrosis

Concert Pharmaceuticals initiates Phase I multiple ascending dose trial with CTP-656 for cystic fibrosis

12 Nov 2015

A novel, potentially disease-modifying treatment for cystic fibrosis for use as monotherapy as well as in combination with other CFTR modulators.

Read more